Table 1.
Clinical, histological, phenotypical and molecular findings in the series of 82 FL
| Gender | F | 46 |
|---|---|---|
| M | 36 | |
| Age | Median 58 | Range 20-88 |
| Type of FL | Nodal FL | 67 |
| Combined FL+DLBCL | 10 | |
| Cutaneous | 5 | |
| Pattern | "In situ neoplasia" | 6 (7.8%) |
| Nodular | 62 (80.5%) | |
| Nodular and diffuse | 5 (6.5%) | |
| Diffuse | 4 (5.2%) | |
| WHO Grade | Grade 1 | 8 (11.3%) |
| Grade 2 | 37 (52.1%) | |
| Grade 3 | 26 (36.6%) | |
| Marginal differentiation | Yes | 7 (9.9%) |
| No | 64 (90.1%) | |
| BCL6 | Positive | 76 (92.7%) |
| Negative | 6 (7.3%) | |
| CD10 | Positive | 74 (90.2%) |
| Negative | 8 (9.8%) | |
| BCL2 | Positive | 72 (87.8%) |
| Negative | 10 (12.2%) | |
| Ki67 antigen | Low | 23 |
| Intermediate | 30 | |
| High | 29 | |
| IGH gene rearrangement | Monoclonal | 66 (80.5%) |
| Polyclonal | 16 (19.5%) | |
| MBR-BCL2/JH rearrangement | Present | 19 (23.2%)/15 (27.3%)* |
| Absent | 63 (76.8%)/40 (72.7%)* | |
* Limited to cases with successful beta-globin gene amplification.